Pregabalin is indicated for:

• Neuropathic pain associated with diabetic peripheral neuropathy (DPN) 
• Postherpetic neuralgia (PHN)
• Adjunctive therapy for the treatment of partial onset seizures in patients 4 years of age and older
• Fibromyalgia 
• Neuropathic pain associated with spinal cord injury

Neuropathy

Neuralgia

Seizure

Fibromyalgia

• Neuropathic Pain Associated with Diabetic Peripheral Neuropathy: In patients with a creatinine clearance of at least 60 mL/min, the maximum recommended dose of LYRICA is 100 mg three times per day (300 mg/day). Begin with 50 mg three times a day (150 mg total). Based on efficacy and tolerability, the dose may be increased to 300 mg/day within one week.
• Postherpetic Neuralgia: In patients with a creatinine clearance of at least 60 mL/min, the recommended dose of LYRICA is 75 to 150 mg twice daily, or 50 to 100 mg three times daily (150 to 300 mg/day). Begin with 75 mg twice a day, or 50 mg three times a day (150 mg/day). Based on efficacy and tolerability, the dose may be increased to  300 mg/day within 1 week.
• Management of Fibromyalgia: The recommended dose of LYRICA for fibromyalgia is 300 to 450 mg/day. Begin dosing at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day).
• Neuropathic Pain Associated with Spinal Cord Injury: The recommended dose range of LYRICA for the treatment of neuropathic pain associated with spinal cord injury is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. 
• Dosing for Adult Patients with Renal Impairment: In view of dose-dependent adverse reactions and since LYRICA is eliminated primarily by renal excretion, adjust the dose in adult patients with reduced renal function.

• Angioedema(e.g., swelling of the throat, head and neck) can occur, and may be associated with life-threatening respiratory compromise requiring emergency treatment. Discontinue LYRICA immediately in these cases. 
• Hypersensitivity reactions(e.g., hives, dyspnea, and wheezing) can occur. Discontinue LYRICA immediately in these patients.
• Increased seizure frequency or other adverse reactions may occur if LYRICA is rapidly discontinued. Withdraw LYRICA gradually over a minimum of 1 week.
• Antiepileptic drugs, including LYRICA, increase the risk of suicidal thoughts or behavior. 
• LYRICA may cause peripheral edema. Exercise caution when co administering LYRICA and thiazolidinedione antidiabetic agents.
• LYRICA may cause dizziness and somnolence and impair patients’ ability to drive or operate machinery